RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2015 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc., a clinical-stage oncology company, announced today the appointment of Glenn P. Muir, CPA, to its board of directors.
“Glenn has been a key architect in the formation and implementation of strategic financial initiatives at global healthcare organizations, positioning companies for financial success,” said Seth Rudnick, MD, Chairman of G1 Therapeutics’ board of directors. “His expertise will be vital to G1 as we advance our lead compounds through clinical development and build a world-class oncology therapeutics company.”
Mr. Muir brings more than 30 years of financial leadership experience to G1’s board. Most recently, he was Executive Vice President and Chief Financial Officer of Hologic, Inc., a multi-billion dollar medical products company. At Hologic, he oversaw the company’s IPO and played a key role in its transition from a single-product, single-disease niche company to a leader in diagnostic and medical imaging systems.
“G1 has generated first-in-class and best-in-class treatments targeting cyclin-dependent kinases, a validated therapeutic class with broad potential,” said Mr. Muir. “The company has built a strong team of biopharma leaders that continues to deliver on its milestones. I look forward to working with G1 to rapidly advance the company, bringing novel oncology therapies to patients and creating value for shareholders.”
Mr. Muir earned an MBA from the Harvard Business School, an M.S. in taxation from Bentley College Graduate School of Business and a bachelor’s degree in business administration from the University of Massachusetts. He was named Boston Business Journal’s 2011 CFO of the Year and one of America’s Best CFOs by Institutional Investor in 2009. Mr. Muir is a member of the American Institute of Certified Public Accountants and the Massachusetts Society of Certified Public Accountants. He also serves on the boards of directors at Raindance Technologies, Inc., Rewalk Robotics LTD, and Repligen Corporation.
About G1 Therapeutics, Inc.
G1 Therapeutics is a clinical-stage oncology company developing novel, small-molecule therapies that address significant unmet needs in patients with cancer. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications. G1 is privately held and based in Research Triangle Park, NC.
Visit www.g1therapeutics.com for more information.
CONTACT: Mark Velleca, MD, PhD
6 Degrees Communications
Source: G1 Therapeutics